- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03413982
Bladder Cancer Longitudinal Biorepository for Development of Novel Therapeutics/Biomarkers (GUB-BCR-001)
May 19, 2022 updated by: University of Kansas Medical Center
The purpose of this study is to create a registry, which is a "bank" of information about patients who have had similar medical conditions and treatments.
The registry will be used by researchers to learn more about long term outcome of patients with bladder cancer, how bladder cancer tissues are related to tumor development, recurrence and survival.
Study Overview
Study Type
Observational
Enrollment (Anticipated)
1000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jane Ladesma
- Phone Number: 913-588-8721
- Email: jledesma2@kumc.edu
Study Locations
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- Recruiting
- University of Kansas Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients who are receiving care from KUMC clinics will be considered for this registry.
Description
Inclusion Criteria:
- Patients who present to clinic with presumed bladder cancer or have a diagnosis of bladder cancer are eligible to participate
- Patients can participate in any additional research studies during the patients' participation within this protocol.
Exclusion Criteria:
- Patients who do not have presumed bladder cancer will not be eligible
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
BC Patients
Patients with bladder cancer.
This registry involves no intervention.
Blood, urine, and tissue samples will be collected to be used for research.
|
Patient registry
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood, urine and tissue characteristics of bladder cancer patients
Time Frame: 24 months
|
Samples will be collected over a 24 month period for patients to build a biorepository for future research on how they are related to tumor development, recurrence and survival.
|
24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: John Taylor, MD, University of Kansas Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 2, 2017
Primary Completion (Anticipated)
January 1, 2030
Study Completion (Anticipated)
January 1, 2035
Study Registration Dates
First Submitted
January 10, 2018
First Submitted That Met QC Criteria
January 26, 2018
First Posted (Actual)
January 29, 2018
Study Record Updates
Last Update Posted (Actual)
May 23, 2022
Last Update Submitted That Met QC Criteria
May 19, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00141546
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bladder Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage III Bladder Cancer | No Evidence of Disease | Stage II Bladder Cancer | Stage IVA Bladder Cancer | Stage IVB Bladder CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteCompletedMuscle-Invasive Bladder Carcinoma | Bladder Cancer Stage II | Bladder Cancer Stage III | Bladder Cancer Stage IVUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnRecurrent Bladder Cancer | Urinary Complications | Stage 0 Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder Cancer
-
Fox Chase Cancer CenterTerminatedStage III Bladder Cancer | Distal Urethral Cancer | Proximal Urethral Cancer | Squamous Cell Carcinoma of the Bladder | Urethral Cancer Associated With Invasive Bladder Cancer | Stage II Bladder CancerUnited States
-
National Cancer Institute (NCI)CompletedStage III Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
National Cancer Institute (NCI)TerminatedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Bladder Adenocarcinoma | Bladder Squamous Cell Carcinoma | Bladder Urothelial Carcinoma | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Stage II Bladder CancerUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Bristol-Myers SquibbRecruitingUrinary Bladder Cancer | Invasive Bladder CancerNetherlands
-
Taris Biomedical LLCBristol-Myers SquibbTerminatedBladder Cancer TNM Staging Primary Tumor (T) T2 | Bladder Cancer TNM Staging Primary Tumor (T) T2A | Bladder Cancer TNM Staging Primary Tumor (T) T2B | Bladder Cancer TNM Staging Primary Tumor (T) T3 | Bladder Cancer TNM Staging Primary Tumor (T) T3A | Bladder Cancer TNM Staging Primary Tumor... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
Clinical Trials on Registry
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...RecruitingAchondroplasia | HypochondroplasiaItaly
-
Emory UniversityRecruiting
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Recruiting
-
University of UlmRecruiting
-
Swiss Hemophilia NetworkRecruiting
-
University of California, San FranciscoAgency for Healthcare Research and Quality (AHRQ)TerminatedProstatic NeoplasmsUnited States
-
University of California, San FranciscoAgency for Healthcare Research and Quality (AHRQ)CompletedHead and Neck NeoplasmsUnited States
-
Christoph AufrichtRecruitingProteinuria | Focal Segmental Glomerulosclerosis | Nephrotic Syndrome | Nephrotic Syndrome Steroid-ResistantAustria
-
Fundación Instituto Valenciano de OncologíaRecruiting
-
University of LouisvilleThe Americas Hepato-Pancreato-Biliary AssociationRecruitingPancreatic CancerUnited States, Canada, Japan, Mexico, Taiwan, United Kingdom